ALK and non-small cell lung carcinoma: Consequently, the current ESMO guideline [11] endorses the first-line treatment of ALK-driven NSCLC with a second-generation TKI, such as alectinib or its comparators brigatinib, ceritinib, or ensartinib [90,91,92].